Everest Medicines (1952) has released a circular detailing multiple proposals for shareholders’ consideration. The company scheduled an Extraordinary General Meeting (EGM) on 24 February 2026 at 10:00 a.m., to be conducted as a virtual meeting. Key items include a commercialization service arrangement, a proposed connected-person award, and the introduction of a 2026 Share Scheme.

According to the circular, Everest Medicines (China) Co., Ltd. signed a Commercialization Service Agreement with Hasten Biopharmaceutical Co., Ltd. The agreement entails exclusive local distribution, marketing, and forecast services for certain core products in the cardiovascular and critical care therapeutic areas, with a deposit of RMB100 million made by Everest Medicines (China). The annual fee caps for the three years ending 31 December 2028 are set at RMB560 million, RMB616 million, and RMB677 million, respectively, and will require independent shareholders’ approval under the Listing Rules due to the connected-party status of Hasten.

The circular also discloses a proposed award grant of 530,303 shares to a newly appointed executive director and chairman, subject to an EGM vote. The vesting schedule stretches over four years. Additionally, the board seeks to adopt the 2026 Share Scheme to replace older share incentive schemes. The 2026 Share Scheme would set a 10% overall share issuance limit and a 0.5% sublimit for service providers as of the date of shareholder approval.

All resolutions related to these proposals will be voted on by poll at the EGM. Shareholders are encouraged to submit proxy forms in advance and attend the virtual meeting via the provided online platform. Shareholders and their proxies can raise questions and cast votes through that platform, in alignment with the details in the circular.